New publication - Dr. George Lau (Principal Investigator, HIMALAYA study)
-
Services
Focus on conducting Phase II, III & IV clinical trials
Provide one-stop service with qualified Principal Investigator,
Experienced research staff & advanced facilities,
Good compliance with GCP & protocol
Patient centered service
High efficiency with fast start-up, high recruitment & retention rate and low screen failure rate
-
Facilities
Locked cabinets & 2-8°C refrigerators for drug storage,
Biological specimen storage area -20°C and -80°C Freezers
Biological Safety Cabinet for drug preparation
Refrigerated centrifuge for sample processing
ECG, Ultrasound, Echo, Holter Monitoring
Endoscopy, IV Infusions system
Imaging scans: X-ray, CT, MRI, PET
-
News & Events
Manuscript acceptance: Title "Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma" has been accepted for publication in Journal of Hepatology (IF=26.8)
Recruiting studies:
Treatment experienced Microsatellite stable Colorectal cancer (MSS CRC)
Intermediate stage of Hepatocellular carcinoma with beyond up-to-7 criteria.
Treatment experienced ER+ and HER2- Locally advanced or metastatic breast cancer
Our Achievements
“Our average retention rate is >90%”
“Average study start-up period is less than 3 months”
-
Randomized 8 patients in 6 months! Top 3 global recruitment site.
An advanced ALK positive NSCLC study
-
Randomized 4 patients, 0% screen failure rate.
A study of advanced HCC with no previous systemic anticancer therapy and a primary biliary cirrhosis study.
-
Randomized 41 patients in total, in which 30 is achieved in 6 months. Top 3 global recruitment site.
A study of unsesectable HCC.
